Resolve FDA cybersecurity deficiency letters fast for imaging AI and SaMD - model lineage, DICOM, cloud tenancy, and PCCP-aligned security responses.
Last reviewed March 2026 · Reviewed against the FDA Feb 3, 2026 final premarket cybersecurity guidance.
Cybersecurity deficiency letters for imaging AI and SaMD typically cluster around three themes: incomplete SBOM (especially missing OS-layer or model artifacts), insufficient threat modeling of the cloud architecture and tenancy boundaries, and missing security architecture views for the inference and writeback paths. We've closed deficiency letters in this segment that were structured exactly that way. Our 48-hour gap analysis maps each item in your AI letter or hold letter to the specific FDA guidance section it references - current 524B guidance, the AI/ML PCCP draft, and the 2026 final premarket guidance - and identifies whether the gap is a documentation problem, an analysis problem, or an actual product-side gap that needs a design change.
For imaging AI specifically, the most common 'real' (not just documentation) gaps we resolve are: tenant-isolation evidence missing for the cloud inference path, model-update path not security-modeled in the PCCP, DICOM security profiles not analyzed, and SBOM that doesn't include model weights or container OS layers. We rebuild the affected SPDF sections, add the missing threat model coverage, regenerate the SBOM with VEX, and produce a response letter structured for the reviewer who issued the deficiency - changes flagged, justifications cross-referenced to guidance sections, and the package eSTAR-ready. We stay engaged through any second round at no additional cost.
Four phases, fixed fee, scoped to imaging & ai/samd architecture from kickoff onward.
Architecture review, attack-surface walkthrough, and threat-model alignment with your team. Written scope in 24 hours.
Every STRIDE entry in your threat model is matched to a planned test case so reviewers see one-to-one coverage.
Device, cloud, mobile, BLE/RF, and OTA channels exercised in parallel by senior engineers - not a single web-app scan.
eSTAR-format report with findings, CVSS, remediation, and retests until every finding with uncontrolled risk is closed.
The patterns we hit in this segment, this service, again and again.
Common pattern: pip-freeze SBOM accepted at first submission, rejected with 'incomplete' on review. We rebuild as multi-layer CycloneDX with model artifacts.
Cloud architecture described, isolation controls not evidenced. Resolved by adding tenant-isolation control test evidence to the SPDF and threat model.
PCCP focuses on clinical performance bounds. Reviewer asks how a malicious model update is prevented - we add that branch to the PCCP cyber controls.
Product uses no DICOM security profile. Response documents the threat-model rationale and compensating controls.
"Blue Goat Cyber takes the burden off our engineers and makes FDA cybersecurity requirements easy to understand. Their expertise and smooth process mean we can focus on our product, not the paperwork. The organized documentation, perfectly formatted for eSTAR, saves us countless hours."
The same deliverables the parent FDA Deficiency Response service ships with - tuned to your imaging & ai/samd architecture.
Reviewer-format documents ready to drop straight into the cybersecurity attachments of your submission - no reformatting on your side.
The Imaging & AI/SaMD baseline, plus the call-outs that matter for fda deficiency response in this segment.
Deficiency responses must cite the exact guidance section. We track the cross-reference to the guidance line, not just the document.
Reviewer expectations for SaMD threat-model rigor are anchored here.
We scope tightly on purpose. These items are either out-of-scope by design or belong in a separate engagement - we'll tell you up front, not after kickoff.
The questions buyers in this segment actually ask before scoping a fda deficiency response engagement.
A practical, ungated buyer's guide for medical device manufacturers evaluating cybersecurity partners, what goes wrong, why it costs you, and what to demand from your next engagement. Aligned to the FDA February 2026 premarket guidance.
A practical, ungated guide to the threat modeling gaps that trigger FDA cybersecurity questions in 510(k), De Novo, and PMA submissions - and exactly how to close them before reviewers find them.
The most common cybersecurity deficiencies in 510(k), De Novo, and PMA submissions, what triggers each one and how to fix it before you file. Aligned to the FDA February 2026 final guidance and Section 524B.
PreSTAR vs eSTAR explained: PreSTAR is the voluntary FDA template for Q-Submissions, eSTAR is required for 510(k) and De Novo. How cybersecurity carries across.
Medical device cybersecurity at each study stage: rodent, large animal, primate, and human trials, and what the FDA expects before your IDE and marketing submission.
What a medical device security advisor does after FDA clearance: keeping the threat model and SBOM current, rating vulnerabilities, and answering hospitals.
Teams in this segment commonly bundle these alongside fda deficiency response.
A 30-minute call with a senior engineer who has done this in imaging & ai/samd before - not a sales rep.
